Medizinische Universitat Innsbruck

Oncotyrol-center for Personalized Cancer Medicine Gmbh (ltd.)

Vichem Chemie Kutato Korlatolt Felelossegu Tarsasag

Lukas A Huber

László Örfi

Péter Bánhegyi

Csaba Szántai-kis

Anna Sípos

Simon Schnaiter

Wáczek Frigyes

Karin Jöhrer

Inge Tinhofer

Johann Jakob Leban

Winfried Wunderlech

János Pató

Richard Greil

The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones, such as for example, N-{4-[1-(2,6-dichloro-4-sulfamoyl-phenyl)-3-dimethylamino-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-ylmethyl]-phenyl}-2-diethylamino-acetamide, particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxis and/or treatment of cancer and other proliferative diseases. Furthermore, the present invention relates to processes for the synthesis of said 3-aminopyrazolo[3,4d]pyrimidin-4-ones and intermediates to be used in the processes of the present invention.

3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors

The present invention relates to the medical and pharmaceutical use of substituted 1H-imidazo[4,5-c]quinolin-4-amines, in particular Imiquimod&#xae; and Gardiquimod&#xae;, alone or preferably in combination with Akt inhibitors, in particular with Akti1/2 and AktX, and most preferably with Akti1/2, in the treatment, prevention and/or amelioration of haematological cancers, in particular multiple myeloma disorders or B-cell disorders, and most particular in the therapy of multiple myeloma.

Medical intervention in haematological cancers

Growing community of inventors

Schwaz, Austria

Lukas A Huber